Virginia's Governor Endorses Important Drug Pricing Reforms for Rare Disease Patients

Virginia's Proactive Drug Pricing Legislation

The Rare Access Action Project (RAAP) expressed its admiration for the recent decision made by Virginia Governor Abigail Spanberger. Her amendments to an existing legislative bill relating to drug pricing signify a notable step forward for patients, particularly those suffering from rare diseases. Here’s a closer look at the implications of these legislative changes.

Legislative Amendments Overview

On April 14, 2026, the Governor took bold action to amend the Prescription Drug Advisory Board (PDAB) provisions in the Senate Bill 271. This step was necessary to ensure thorough scrutiny of controversial payment limit measures linked to the Maximum Fair Price (MFP) outlined in the Inflation Reduction Act for Medicare. Notably, the Governor’s move mandates that the General Assembly re-evaluate the proposed upper payment limit (UPL) authority after an extensive study period through 2026. Only after this careful examination will the legislature be required to vote again in 2027 to either authorize the proposed policies or discard them altogether.

Significance for Virginia Patients

RAAP’s Executive Director, Michael Eging, emphasized that this legislative amendment is a major victory for patients in Virginia. He stated, “Today is a tremendous win for patients in Virginia. The Governor's action ensures that the MFP-based UPL policy will receive the careful, transparent review it deserves.” The importance of this scrutiny cannot be overstated, as policies such as UPLs often create complex ramifications for access to specialized therapies, particularly for smaller patient groups, potentially limiting their treatment options.

Eging extended gratitude to the RAAP community for their invaluable feedback, which informed legislators of the potential adverse effects of the proposed legislation on patient access. He also praised Governor Spanberger’s commendable resolve to advocate for rare disease patients.

Additional Legislative Milestone: Capped Co-Pay Law

In addition to the amendments on the PDAB legislation, RAAP applauded the recent signing of a capped co-pay legislation, encompassing House Bills 625 and 161. This development reflects the growing support in the Virginia legislature for making healthcare more affordable for patients, particularly those grappling with rare diseases.

The bipartisan cooperation seen throughout this legislative session played a crucial role in advancing this co-pay cap law, which is expected to provide patients with predictable and limited out-of-pocket costs when accessing their necessary treatments. Eging voiced his appreciation for the leadership demonstrated by lawmakers and advocacy groups, like Blood Cancer United, saying, “We are deeply grateful to Blood Cancer United and the unwavering efforts of patients who helped get this across the finish line.”

A Coalition for Change

The RAAP is dedicated to exploring innovative policy solutions that address access issues for patients with rare conditions. Their mission firmly aligns with the goal of ensuring that individuals with rare diseases have unimpeded access to the essential care and therapies they require. By advocating for such transformative policies, RAAP continues to be a leading voice in the pursuit of equitable healthcare.

As Virginia moves forward with these reforms, the journey toward improved drug pricing and accessibility stands as a testament to the power of collaboration between legislators, advocacy groups, and the communities they serve. This legislative momentum inspires hope and progress for rare disease patients not only in Virginia but across the nation.